Advanced Cancers Clinical Trial
Official title:
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
Objectives:
The primary objective of the research project is to investigate how declining health status
influences the end-of-life (EOL) treatment preferences in Latino Medicare beneficiaries with
cancer and to examine if and how these preferences are modified by predisposing
characteristics (i.e., acculturation, education, medical mistrust, perceived racism) and/or
provider-related characteristics (i.e., ethnicity, language used, provision of interpreters,
or patient navigators). The specific aims are:
1. To determine if declining functional status influences the end-of-life treatment
preferences of older Latino Medicare beneficiaries with cancer.
2. To determine if predisposing characteristics (i.e., acculturation, age, education,
medical mistrust, perceived racism) and/or provider-related characteristics (i.e.,
ethnicity, language used, provision of interpreters, or patient navigators) modify the
association between end-of-life treatment preferences and declining health status in
older Latino Medicare beneficiaries with cancer.
3. To identify if the end-of-life treatment preferences of Latino Medicare beneficiaries
with cancer differ from those of older Medicare beneficiaries without cancer.
Latino Medicare Beneficiary With Cancer:
This study will determine if the combination of declining health, cultural factors (such as
language of choice) and meeting the cultural and language needs of Latino cancer patients
influence end-of-life treatment choices over time.
If participant decides to take part in this study, participant will complete a questionnaire
once a month for 9 months, over the telephone. The questionnaire asks participant about
participant's end of life and decision making preferences, as well as questions about
participant's health status and other basic questions about participant such as participant's
education level, age, and health insurance. The first phone questionnaire, the one
participant will answer today, will take about 30 - 40 minutes to complete. The monthly
surveys after today will take about 20 - 30 minutes to complete each month. Participant will
be considered off of the study in nine months.
Should participant become too ill and are unable to complete the surveys, researchers will
ask a proxy to respond on participant's behalf. A proxy in this case, should be someone
participant trusts, who knows participant well enough to know how to answer the health
questionnaire on participant's behalf. A proxy is usually a spouse, child, other close family
member or friend. This person will only have to answer questions about participant. He or she
will not answer any questions about him or herself. Researchers will ask participant to
provide researchers with the contact information of the person participant selects as
participant's "questionnaire proxy" today at the end of this consent form. If participant is
able to complete all 9 surveys, researchers will not contact the proxy.
Information from this study will be used only for research purposes. All identifying
information such as participant's name and address will be kept private. This information may
be kept at MD Anderson and University of Houston (UH) forever. Participant will be assigned a
code number so that participant's name will not be used. The research team at MD Anderson and
UH will be able to link the code number to participant's name. Researchers will take
appropriate steps to keep participant's survey responses confidential. However, there is no
guarantee of absolute confidentiality. Participant's information will be protected according
to state and federal law. The research team may share study information with certain
individuals including the National Institutes of Health and institutional study monitors who
verify the accuracy of the information to see that the research is being conducted in a safe
and correct manner.
Answering the survey questions over the phone may cause participant to feel tired. The
questionnaires may involve topics that are sensitive in nature. Participant may refuse to
answer any question that makes participant feel uncomfortable. If participant has concerns
after completing the survey, participant is encouraged to contact participant's doctor, the
study chair, or MD Anderson's Institutional Review Board.
Latino Medicare Beneficiary Without Cancer:
This study will determine if the combination of declining health, cultural factors (such as
language of choice) and meeting the cultural and language needs of Latino cancer patients
(provider ethnicity, use of interpreters), influence end-of-life treatment choices over time.
If participant decides to take part in this study, participant will complete a one-time
questionnaire today, over the telephone. The questionnaire asks participant about
participant's end of life and decision making preferences, as well as questions about
participant's health status and other basic questions about participant such as participant's
education level, age, and health insurance. This questionnaire will take about 30 - 40
minutes to complete. Participant will be considered off the study after participant completes
this one-time questionnaire.
Information from this study will be used only for research purposes. All identifying
information such as participant's name and address will be kept private. This information may
be kept at MD Anderson and University of Houston (UH) forever. Participant will be assigned a
code number so that participant's name will not be used. The research team at MD Anderson and
UH will be able to link the code number to participant's name. Researchers will take
appropriate steps to keep participant's survey responses confidential. However, there is no
guarantee of absolute confidentiality. Participant's information will be protected according
to state and federal law. The research team may share study information with certain
individuals including the National Institutes of Health and institutional study monitors who
verify the accuracy of the information to see that the research is being conducted in a safe
and correct manner.
Answering the survey questions over the phone may cause participant to feel tired. The
questionnaires may involve topics that are sensitive in nature. Participant may refuse to
answer any question that makes participant feel uncomfortable. If participant has concerns
after completing the questionnaires and interviews, participant is encouraged to contact
participant's doctor or the study chair.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |